Teixeira M M, Gristwood R W, Cooper N, Hellewell P G
Imperial College of Medicine, National Heart and Lung Institute, London, UK.
Trends Pharmacol Sci. 1997 May;18(5):164-71. doi: 10.1016/s0165-6147(97)01049-3.
Phosphodiesterase type 4 (PDE4) plays a major role in modulating the activity of virtually all cells involved in the inflammatory process. Inhibitors of this enzyme family display impressive anti-inflammatory and disease-modifying effects in a variety of experimental models. In this review, Mauro Teixeira, Robert Gristwood, Nicola Cooper and Paul Hellewell examine the capacity of PDE4 inhibitors to exert anti-inflammatory actions in vivo and discuss the potential of this class of drugs to take their place as novel therapeutic agents for a variety of inflammatory diseases.
4型磷酸二酯酶（PDE4）在调节几乎所有参与炎症过程的细胞的活性方面发挥着主要作用。该酶家族的抑制剂在多种实验模型中显示出令人印象深刻的抗炎和疾病修饰作用。在这篇综述中，毛罗·特谢拉、罗伯特·格里斯伍德、尼古拉·库珀和保罗·赫勒韦尔研究了PDE4抑制剂在体内发挥抗炎作用的能力，并讨论了这类药物作为多种炎症性疾病新型治疗药物的潜力。
